Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Prime Medicine, Inc. develops genetic medicines using its proprietary Prime Editing platform, which is designed to make targeted edits within genes. News about PRME centers on its pipeline for genetically defined diseases, including PM577 for Wilson Disease, PM647 for Alpha-1 Antitrypsin Deficiency and PM359, an investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease.
Company updates also cover financial results, regulatory interactions, clinical-data publications, investor conference participation and finance leadership changes. Additional recurring themes include an in vivo cystic fibrosis program supported by the Cystic Fibrosis Foundation and Prime Edited CAR-T product development with Bristol Myers Squibb for hematology, immunology and oncology.
Prime Medicine (Nasdaq: PRME) announced that CEO Allan Reine, M.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:40 a.m. ET in Miami Beach, FL.
A live audio webcast and 90-day replay will be available in the News & Events section of Prime Medicine’s website.
Prime Medicine (Nasdaq: PRME) announced that CEO Allan Reine, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 p.m. ET in New York.
A live audio webcast and a 90-day replay will be available in the News & Events section of the company’s website.
Prime Medicine (Nasdaq: PRME) reported Q1 2026 results and program updates on May 7, 2026. Key points: cash and investments $149.2M as of March 31, 2026, providing a runway into 2027; net loss $49.1M for Q1; R&D $34.1M and G&A $17.4M. The company is on track to file IND/CTA for PM577 (Wilson Disease) H1 2026 and PM647 (AATD) mid-2026, with initial clinical data expected in 2027, and continues regulatory dialogue toward a potential BLA for PM359 (CGD).
Prime Medicine (Nasdaq: PRME) appointed Svetlana Makhni as Chief Financial Officer, effective April 16, 2026. Ms. Makhni will lead financial operations, investor relations, financial planning and corporate development.
She brings over 20 years of biotech and investment banking experience, including prior CFO roles and work on strategic transactions with Ipsen and Gilead Sciences. The company said her hire supports planned clinical entry for Wilson Disease and Alpha-1 Antitrypsin Deficiency and broader Prime Editing programs.
Prime Medicine (Nasdaq: PRME) reported full‑year 2025 results and provided program updates on March 3, 2026. Key clinical and financial points: cash and investments $191.4M, net loss $201.1M, R&D $160.6M and G&A $52.3M. The company plans IND/CTA filings for Wilson Disease and AATD in 1H and mid‑2026, with initial clinical data expected in 2027.
Regulatory progress includes ongoing FDA engagement for PM359 in CGD and intent to submit a BLA; NEJM publication of PM359 Phase 1/2 data was announced.
Prime Medicine (Nasdaq: PRME) said management will participate in three investor conferences in early March 2026: TD Cowen (fireside chat, Mar 4, 2026, 1:10 p.m. ET, Boston), Jefferies Biotech on the Beach (1x1 meetings, Mar 10, 2026, Miami Beach) and Citizens Life Sciences (fireside chat, Mar 11, 2026, 2:15 p.m. ET, Miami Beach).
Live audio webcasts of the fireside chats will be available under Events & Presentations on the company website, with replays accessible for 90 days.
Prime Medicine (Nasdaq: PRME) announced that Allan Reine, M.D., CEO, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:00 a.m. PT (12:00 p.m. ET) in San Francisco.
A live audio webcast will be available under Events & Presentations on the company's website at www.primemedicine.com, and a replay will remain accessible on the Prime Medicine website for 90 days after the event.
Prime Medicine (Nasdaq: PRME) announced publication in the New England Journal of Medicine of Phase 1/2 data for PM359, its investigational autologous HSC product for p47phox chronic granulomatous disease (CGD), with results also presented at the 67th ASH Annual Meeting (Dec 6-9, 2025).
Two patients showed rapid neutrophil and platelet engraftment, achieving 69% and 83% DHR+ neutrophils by Day 30 (above a 20% clinical threshold), durable NADPH oxidase activity, early clinical benefit (cessation of mesalamine in Patient 1; marked fecal calprotectin reduction and symptom improvement in Patient 2), and no clinically significant adverse events attributed to PM359; observed toxicities were consistent with busulfan-based conditioning.
Prime Medicine (Nasdaq: PRME) announced that Allan Reine, M.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 11:15 a.m. ET in Coral Gables, FL.
A live audio webcast will be available under “Events & Presentations” in the News & Events section of the company website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the event.
Prime Medicine (Nasdaq: PRME) announced that Allan Reine, M.D., Chief Executive Officer, will speak in a fireside chat at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 at 12:00 noon GMT (7:00 a.m. ET) in London.
A live audio webcast will be available under “Events & Presentations” in the News & Events section of the company website at www.primemedicine.com, and a replay will be accessible on the website for 90 days after the event.